http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105663099-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
filingDate | 2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105663099-B |
titleOfInvention | Purposes of the aloe-emodin in preparation reducing blood lipid and liver lipid lowering drug |
abstract | The invention discloses purposes of the aloe-emodin in preparation reducing blood lipid and liver lipid lowering drug, belong to pharmaceutical technology field.Wherein, the blood lipid refers to that total cholesterol and low-density lipoprotein in serum, liver rouge refer to the total cholesterol in liver.Toxicity test shows aloe-emodin without obvious toxic-side effects.The effect experiment of aloe-emodin shows that it can significantly reduce the total cholesterol and low-density lipoprotein in hyperlipemia animal model serum, has apparent effect for reducing blood fat;Aloe-emodin can also significantly reduce the content of total cholesterol in hyperlipemia animal model liver simultaneously, have apparent liver lipid lowering effect.Therefore, the invention proposes aloe-emodins to reduce the purposes in blood lipid and liver rouge, and effect for reducing fat is significant, toxicity is low, nonirritant, and price is low, it is easy to produce, transport, store and take, will have broad application prospects as the drug of reducing blood lipid and liver lipid lowering. |
priorityDate | 2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.